Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-06-07 00:00:00 ET · period of report 2024-06-05 · accession 0001601830-24-000077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-07 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 833.7K | +3% | $0 |
| D | 2024-06-07 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 808.7K | -3% | $0 |
| DM | 2024-06-07 | 2024-06-05+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $8.71 | -100.0K | 708.7K | -12% | -$871.0K |
| D | 2024-06-07 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -25.0K | 6.40M | -0.4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-06-05 | C | A | 25,000 | $0.00 | 833,738 | D | — | — | |
| 2 | Common | Class A Common Stock | 2024-06-05 | G | D | 25,000 | $0.00 | 808,738 | D | — | — | |
| 3 | Common | Class A Common Stock | 2024-06-05 | S | D | 50,000 | $8.42 | 758,738 | D | — | — | |
| 4 | Common | Class A Common Stock | 2024-06-06 | S | D | 50,000 | $9.00 | 708,738 | D | — | — | |
| 5 | Derivative | Class B Common Stock | 2024-06-05 | C | D | 25,000 | $0.00 | 6,401,700 | D | $0.00 · — to — | 25,000 Class A Common Stock | (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |